2. Signaling Pathways
  3. Anti-infection
    Metabolic Enzyme/Protease
  4. HIV Protease

HIV Protease

HIV Protease

Related Products

PDF 0.19 MB

HIV protease, a homodimeric aspartyl protease, is crucial for the viral life-cycle, cleaving proviral polyproteins, hence creating mature protein components that are required for the formation of an infectious virus. HIV protease cleaves newly synthesized polyproteins at the appropriate places to create the mature protein components of an infectious HIV virion. HIV protease is a critical drug target in designing anti-retroviral drugs to treat HIV/AIDS (acquired immune deficiency syndrome).

HIV-1 protease permits viral maturation by processing the Gag and Gag-Pro-Pol polyproteins. It recognizes and cleaves more than 12 different substrates leading to viral maturation. Similar to that of HIV-1, HIV-2 protease is also a homodimeric aspartyl enzyme that plays a vital role in the HIV life-cycle through processing of Gag and Gag-Pro-Pol precursor polyproteins leading to viral maturation.

HIV Protease Related Products (124):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P0018
    Pepstatin
    		Inhibitor 99.90%
    Pepstatin (Pepstatin A) is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin also inhibits HIV protease.
    Pepstatin
  • HY-90001
    Ritonavir
    		Inhibitor 99.96%
    Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.
    Ritonavir
  • HY-14588
    Lopinavir
    		Inhibitor 99.87%
    Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM.
    Lopinavir
  • HY-15287
    Nelfinavir
    		Inhibitor 98.83%
    Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent.
    Nelfinavir
  • HY-17007
    Saquinavir
    		Inhibitor 99.73%
    Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.36 μM.
    Saquinavir
  • HY-169166
    HIV-1 protease-IN-14
    		Inhibitor
    HIV-1 protease-IN-14 (compound 5ae) is a potent HIV-1 protease inhibitor with Ki values of 0.28, 56.9 nM for WT HIV-1 PR, R41T HIV-1 PR, respectively. HIV-1 protease-IN-14 shows low cytotoxicity.
    HIV-1 protease-IN-14
  • HY-124360
    NIT
    		Inhibitor
    NIT is an inhibitor of HIV-1 protease (HIV-1p) with Ki values of 96 and 91 μM for WT HIV-1p and MDR HIV-1p, respectively.
    NIT
  • HY-120812
    HIV-IN-11
    		Inhibitor
    HIV-IN-11 is part of the hydroxylaminoglutaramide (HAPA) transition state isomeric series of HIV protease inhibitors and is a potent and selective inhibitor of HIV-1 protease. HIV-IN-11 competitively inhibits HIV-1 PR (Ki: 0.049 nM) and potently inhibits replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. HIV-IN-11 displays a longer half-life than indinavir sulfate in animal models and serves as a promising second-generation HIV protease inhibitor.
    HIV-IN-11
  • HY-B0689A
    Indinavir sulfate
    		Inhibitor 99.97%
    Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a SARS-CoV 3CLpro inhibitor.
    Indinavir sulfate
  • HY-17040
    Darunavir
    		Inhibitor 99.91%
    Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC50 = 0.003 μM; IC90 = 0.009 μM) with minimal cytotoxicity.
    Darunavir
  • HY-15148
    Tipranavir
    		Inhibitor ≥98.0%
    Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM. Tipranavir inhibits SARS-CoV-2 3CLpro activity.
    Tipranavir
  • HY-17003
    Saquinavir mesylate
    		Inhibitor 99.84%
    Saquinavir Mesylate (Ro 31-8959/003) is an HIV protease inhibitor used in retrovirus research.
    Saquinavir mesylate
  • HY-15287A
    Nelfinavir Mesylate
    		Inhibitor 98.93%
    Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir Mesylate (AG 1343 Mesylate) is a broad-spectrum, anticancer agent.
    Nelfinavir Mesylate
  • HY-17367A
    Atazanavir sulfate
    		Inhibitor 99.94%
    Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM.
    Atazanavir sulfate
  • HY-P0018B
    Pepstatin Ammonium
    		Inhibitor 99.76%
    Pepstatin (Pepstatin A) Ammonium is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Ammonium also inhibits HIV protease.
    Pepstatin Ammonium
  • HY-17430
    Amprenavir
    		Inhibitor 99.53%
    Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.
    Amprenavir
  • HY-P0018A
    Pepstatin Trifluoroacetate
    		Inhibitor 98.88%
    Pepstatin (Pepstatin A) Trifluoroacetate is a specific, orally active aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Trifluoroacetate also inhibits HIV protease.
    Pepstatin Trifluoroacetate
  • HY-17367
    Atazanavir
    		Inhibitor 99.86%
    Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM.
    Atazanavir
  • HY-17041
    Darunavir Ethanolate
    		Inhibitor 99.93%
    Darunavir ethanolate (TMC114 Ethanolate) is a potent HIV protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a Ki of 1 nM for wild type HIV-1 protease.
    Darunavir Ethanolate
  • HY-107123
    TMC310911
    		Inhibitor 99.90%
    TMC310911 is a potent and orally active HIV type-1 (HIV-1) protease inhibitor with EC50 values ranged from 2.2 nM to 14.2 nM for wild-type HIV-1. TMC310911 has potent activity against a wide spectrum of recombinant HIV-1 isolates. TMC310911 has strong antiviral activity.
    TMC310911